Abstract: P942
Type: Poster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Background: Corpus Callosum Index (CCI) is a fast and easy to perform method to quantify corpus callosum atrophy, and has been widely used in patient with MS, with significant correlations with cognitive impairment and disability. There are no studies with CCI in epilepsy.
Objective: To evaluate the longitudinal CCI measurements in patients with MS with and without epilepsy and associations with seizure control.
Methods: Retrospective study. Global, regional and annualized CCI atrophy rate were measured in a best mid-sagittal T2/FLAIR or T1 MRI in a 1.5T scanner in two time points with a separation of more than one year between scans. We evaluate differences in patients with relapsing-remitting MS, with and without epilepsy, and with good or poor seizure control (persistence of seizures or status epilepticus). Associations between CCI, disability (EDSS) and baseline neuropsychological performance were also assessed.
Results: We included 55 patients with MS, 40 without epilepsy, 9 with good epilepsy control and 5 with poor epilepsy control. Mean age 36.4 years, 65% women, mean disease duration 9.8 years, median EDSS 1.5, and mean interval between MRI of 3.8 years. Mean age, gender proportion and EDSS did not differ between groups, although patients with epilepsy had longer disease durations (p=0.001). In the whole MS group, we found a cross-sectional direct correlation between global CCI and neurocognitive tests (processing speed Rho 0.46, p=0.002 and working memory Rho 0.42, p=0.005), and an inverse correlation with EDSS (Rho -0.40, p=0.009). Mean annualized CCI atrophy rate of MS patients without epilepsy was (0.15% ± 2.66), MS with good epilepsy control (-0.60% ± 1.37) and MS with poor epilepsy control (-3.56% ± 2.44, p=0.008). Posterior CCI annualized atrophy rate was also significantly larger in patients with poor epilepsy control (-3.61% ± 2.23, p=0.03).
Conclusion: CCI is a time-effective and probable valuable biomarker of neurodegeneration in patients with different neurological disorders. Evaluation of annualized CCI rate in patients with epilepsy without MS could also be useful to validate CCI as a relevant outcome in this disease.
Disclosure:
Reinaldo Uribe-San-Martin reports no disclosures
Ethel Ciampi reports no disclosures
Macarena Vasquez reports no disclosures
Claudia Cárcamo reports no disclosures
Abstract: P942
Type: Poster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Background: Corpus Callosum Index (CCI) is a fast and easy to perform method to quantify corpus callosum atrophy, and has been widely used in patient with MS, with significant correlations with cognitive impairment and disability. There are no studies with CCI in epilepsy.
Objective: To evaluate the longitudinal CCI measurements in patients with MS with and without epilepsy and associations with seizure control.
Methods: Retrospective study. Global, regional and annualized CCI atrophy rate were measured in a best mid-sagittal T2/FLAIR or T1 MRI in a 1.5T scanner in two time points with a separation of more than one year between scans. We evaluate differences in patients with relapsing-remitting MS, with and without epilepsy, and with good or poor seizure control (persistence of seizures or status epilepticus). Associations between CCI, disability (EDSS) and baseline neuropsychological performance were also assessed.
Results: We included 55 patients with MS, 40 without epilepsy, 9 with good epilepsy control and 5 with poor epilepsy control. Mean age 36.4 years, 65% women, mean disease duration 9.8 years, median EDSS 1.5, and mean interval between MRI of 3.8 years. Mean age, gender proportion and EDSS did not differ between groups, although patients with epilepsy had longer disease durations (p=0.001). In the whole MS group, we found a cross-sectional direct correlation between global CCI and neurocognitive tests (processing speed Rho 0.46, p=0.002 and working memory Rho 0.42, p=0.005), and an inverse correlation with EDSS (Rho -0.40, p=0.009). Mean annualized CCI atrophy rate of MS patients without epilepsy was (0.15% ± 2.66), MS with good epilepsy control (-0.60% ± 1.37) and MS with poor epilepsy control (-3.56% ± 2.44, p=0.008). Posterior CCI annualized atrophy rate was also significantly larger in patients with poor epilepsy control (-3.61% ± 2.23, p=0.03).
Conclusion: CCI is a time-effective and probable valuable biomarker of neurodegeneration in patients with different neurological disorders. Evaluation of annualized CCI rate in patients with epilepsy without MS could also be useful to validate CCI as a relevant outcome in this disease.
Disclosure:
Reinaldo Uribe-San-Martin reports no disclosures
Ethel Ciampi reports no disclosures
Macarena Vasquez reports no disclosures
Claudia Cárcamo reports no disclosures